Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-05-06 | Alzinova | BioStock: Alzinovas avgående vd kommenterar bolagets potential | Pressreleaser | Visa Stäng |
|
||||
2024-04-26 | Alzinova | KALLELSE TILL ÅRSSTÄMMA I ALZINOVA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-26 | Alzinova | NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL)The shareholders of Alzinova AB (publ) reg. no. 556861-8168 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 29 May 2024 at 13.00 CEST at Chalmersska Huset (address Södra Hamngatan 11) in Gothenburg. Registration starts at 12.30 CEST. Right to participate Nominee-registered shares Proxy Proposal of agenda Proposals The Nomination Committee’s proposals (item 2 and 9-14) The Board of Directors’ proposals Allocation of the Company’s profit or loss (item 8.b) Resolution on directed issue of shares (item 15) The Board of Directors proposes that the AGM resolves on an issue of shares (the “ Compensation Issue ”), with deviation from the shareholders’ pre-emption rights as follows. 1. The share capital is increased with not more than SEK 1,700,174.546 through an issue of not more than 6,464,542 shares. 2. The right to subscribe for the new shares shall, with deviation from the shareholders’ pre-emption rights, accrue to the underwriters with whom the Company has entered into an underwriting agreement to secure the Rights Issue. The purpose of the Compensation Issue and the reason for the deviation from the shareholders’ pre-emption rights is that any underwriting compensation to the underwriters may be paid through a new issue of shares which the board considers favorable for the Company’s shareholders as it has a positive effect on the Company’s liquidity. 3. The subscription price for each share shall be SEK 0.90. The subscription price in the Compensation Issue was negotiated at arm’s length in connection with the procurement of the underwriting commitments, which took place in consultation with the financial advisor and after an analysis of customary market factors. The Board’s assessment is that the subscription price, and other conditions in the Compensation Issue, against this background, are market conformant. 4. The part of the subscription price for the shares that exceeds the quota value of the share shall be added to the non-restricted share premium reserve. 5. The newly issued shares shall be subscribed for on subscription list no later than 5 July 2024. The Board has the right to extend the subscription period. 6. Payment for subscribed shares shall be made by way of set-off no later than 5 July 2024, whereby set-off of the subscription price can be made at a maximum amount corresponding to the subscriber’s claim according to entered into underwriting agreements. The total claims amount to SEK 5,818,089.24. Over-subscription is not possible. Set-off is completed through subscription of shares. The Board has the right to extend the time for payment. 7. The new shares shall be entitled to dividend as from the first record day for dividend that falls closest after the newly issued shares have been registered by the Swedish Companies Registration Office (Sw. Bolagsverket) and in the Company’s share register held by Euroclear Sweden AB. The Company’s CEO shall be authorised to make any formal adjustments in the resolution that may be required in connection with registration with the Swedish Companies Registration Office (Sw. Bolagsverket). Proposal for a resolution to amend the Articles of Association (item 16) It is proposed that the limits for the share capital in § 4 of the Articles of Association be amended as follows: “The share capital shall be a minimum of SEK 21,040,000 and a maximum of SEK 84,160,000.” Furthermore, it is proposed that the limits for the number of shares in § 5 of the Articles of Association be amended as follows: “The number of shares shall be a minimum of 80,000,000 and a maximum of 320,000,000.” Authorisation for the Board of Directors to resolve on new issues of shares or warrants (item 17) The number of shares that can be issued, or, in the event of an issue of warrants, added after exercise, with the support of the authorization shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered Articles of Association. The reason for the proposal and the possibility of deviation from the shareholders’ pre-emption rights is to broaden and strengthen the ownership with strategic shareholders, procuring or facilitating the procurement of working capital, increasing the liquidity of the share, making acquisitions, or procuring or facilitating the procurement of capital for acquisitions. The Company’s CEO shall be authorized to make the minor formal adjustments to the resolution that may prove necessary in connection with registration with the Swedish Companies Registration Office. Majority requirements Further information The annual report, audit report and proxy forms, as well as complete underlying documentation will be made available by the Company and at the Company’s website at least three weeks before the AGM. The documents will be sent to shareholders who request it and who provide their postal address. The shareholders are reminded of their right of information according to Chapter 7 Section 32 of the Swedish Companies Act (Sw: aktiebolagslagen). The Company has its registered office in Gothenburg. Processing of personal data Gothenburg, April 2024 |
||||
2024-04-26 | Alzinova | Styrelsen beslutar om en företrädesemission av aktier om cirka 34,4 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-26 | Alzinova | The Board of Directors resolves on a rights issue of shares of approximately SEK 34.4 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Alzinova | Kristina Torfgård lämnar VD-posten på Alzinova AB i juli 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Alzinova | Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Alzinova | BioStock: Alzinovas CSO kommenterar nya analysdata för ALZ-101 i Alzheimers sjukdom | Pressreleaser | Visa Stäng |
|
||||
2024-04-11 | Alzinova | Alzinova: Fördjupad analys påvisar positiv trend för biomarkörer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Alzinova | Alzinova: In-depth analysis shows positive trend in biomarkers | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Alzinova | BioStock: Alzinova når ytterligare milstolpe i Alzheimerstudie | Pressreleaser | Visa Stäng |
|
||||
2024-04-04 | Alzinova | Alzinova - All patients in the extension part of the phase 1b study have received their last dose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-04 | Alzinova | Alzinova - Samtliga patienter i fas 1b-studiens förlängningsdel har fått sin sista dos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Alzinova | Alzinova appoints Erik Kullgren as interim CFO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Alzinova | Alzinova utser Erik Kullgren som interim CFO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-05 | Alzinova | Alzinova presenterar på investerarträffar i mars | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-05 | Alzinova | Alzinova presents at investor meetings in March | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Alzinova | BioStock: Alzinova siktar på partnerskap för Alzheimerstudien | Pressreleaser | Visa Stäng |
|
||||
2024-02-29 | Penser Future by Carnegie | Penser Future by Carnegie: Alzinova - Huvudfokus för 2024 är att teckna ett partneravtal | Pressreleaser | Visa Stäng |
|
||||
2024-02-28 | Redeye | Redeye: Alzinova Q4 – With wind in the sails | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Alzinova | Alzinova offentliggör bokslutskommuniké för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Alzinova | Alzinova publishes Year-end report 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Alzinova | BioStock: Alzinova får grönt ljus att öka dosen i Alzheimerstudie | Pressreleaser | Visa Stäng |
|
||||
2024-02-13 | Alzinova | Alzinova receives regulatory approval to evaluate a higher dose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Alzinova | Alzinova får myndighetsgodkännande att utvärdera en högre dos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Alzinova | Alzinova till BioStock: "Vi har ett starkt case med vår Alzheimerkandidat" | Pressreleaser | Visa Stäng |
|
||||
2024-01-30 | Alzinova | Alzinova: Primary analysis confirms positive phase 1b results with ALZ-101 against Alzheimer’s | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Alzinova | Alzinova: Primär analys bekräftar positiva fas 1b-resultat med ALZ-101 mot Alzheimers | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-08 | Alzinova | BioStock: Alzinova's CMO wants to bring forward a vaccine against Alzheimer's | Pressreleaser | Visa Stäng |
|
||||
2023-12-11 | Penser Future by Carnegie | Penser Future by Carnegie: Alzinova - Therapeutic Alzheimer's vaccine in the spotlight | Pressreleaser | Visa Stäng |
|
||||
2023-12-07 | Penser Future by Carnegie | Penser Future by Carnegie: Intervju med Alzinova - Carnegie Investment Bank - 7 dec 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-12-04 | Alzinova | BioStock: Alzinovas vd kommenterar positiva topline-data | Pressreleaser | Visa Stäng |
|
||||
2023-12-04 | Redeye | Redeye: Alzinova - Positive topline results | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-01 | Penser Future by Carnegie | Penser Future by Carnegie: Positiva topline-resultat från den kliniska fas Ib-studien - Alzinova | Pressreleaser | Visa Stäng |
|
||||
2023-12-01 | Alzinova | Alzinovas CFO avser gå i pension och Bolaget inleder rekryteringsprocessen för en efterträdare | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-01 | Alzinova | Alzinova's CFO plans for retirement and the Company initiates a recruitment process for a successor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Alzinova | Alzinova announces positive phase 1b results with the vaccine candidate ALZ-101 against Alzheimer's disease | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Alzinova | Alzinova meddelar positiva fas 1b-resultat med vaccinkandidaten ALZ-101 mot Alzheimers sjukdom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-21 | Penser Future | Penser Future: Terapeutiskt vaccin mot Alzheimers sjukdom i fokus - Alzinova AB | Pressreleaser | Visa Stäng |
|
||||
2023-11-20 | Alzinova | Alzinova presenterar på Erik Penser Banks Bolagsdag den 23 november | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-20 | Alzinova | Alzinova presents at Erik Penser Bank's Investor Day on November 23rd | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-06 | Alzinova | BioStock: Alzinova om förväntningarna inför BIO-Europe | Pressreleaser | Visa Stäng |
|
||||
2023-11-02 | Redeye | Redeye: Alzinova Q3 - All eyes on the readout | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Alzinova | Alzinova AB delårsrapport för januari - september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Alzinova | Alzinova AB interim report January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-24 | Alzinova | Alzinova engages Erik Penser Bank as liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-24 | Alzinova | Alzinova anlitar Erik Penser Bank som likviditetsgarant | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Alzinova | Alzinova deltar under hösten vid Europas största Life science-konferens och investerarträffar | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Alzinova | Alzinova will attend Europe's largest Life Science conference and investor meetings this fall | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-28 | Alzinova | BioStock: Alzinova säkrar regulatoriskt stöd från EMA | Pressreleaser | Visa Stäng |
|
||||
2023-09-26 | Alzinova | Alzinova receives positive response from the European Medicines Agency EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-26 | Alzinova | Alzinova erhåller positivt svar från European Medicines Agency EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-21 | Alzinova | Alzinova intervjuas hos Redeye i samband med World Alzheimer’s Day | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-21 | Alzinova | Alzinova interviewed by Redeye in connection with World Alzheimer's Day | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-11 | Alzinova | BioStock: Alzinovas vd sammanfattar 2023 och blickar framåt | Pressreleaser | Visa Stäng |
|
||||
2023-08-25 | Alzinova | Alzinova inleder samarbete med PolyPeptide | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Alzinova | Alzinova initiates collaboration with PolyPeptide | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-17 | Redeye | Redeye: Alzinova Q2 2023 - Proactive preparations | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-17 | Alzinova | Alzinova AB delårsrapport för januari - juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-17 | Alzinova | Alzinova AB interim report January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-10 | Alzinova | BioStock: Alzinova meddelar positiva samtal med FDA | Pressreleaser | Visa Stäng |
|
||||
2023-08-09 | Alzinova | Alzinova progresses following positive Pre-IND meeting with FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Alzinova | Alzinova avancerar efter positivt Pre-IND-möte med FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-03 | Alzinova | Alzinova recruits Kirsten Harting as new Chief Medical Officer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-03 | Alzinova | Alzinova rekryterar Kirsten Harting som ny Chief Medical Officer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Alzinova | BioStock: Alzinovas vd om kontakterna med FDA och EMA - BioStock | Pressreleaser | Visa Stäng |
|
||||
2023-06-13 | Alzinova | Alzinova submits request for Pre-IND meeting with FDA and applies for EMA Scientific Advice | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Alzinova | Alzinova ansöker om Pre-IND möte med FDA och EMA Scientific Advice | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Alzinova | Bulletin from the annual general meeting of Alzinova AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Alzinova | Kommuniké från årsstämma i Alzinova AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-29 | Alzinova | First patient dosed in the extension part of the phase 1b study with ALZ-101 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-29 | Alzinova | Första patienten doserad i förlängningsdelen av fas 1b studien med ALZ-101 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Redeye | Redeye: Alzinova Q1 2023 - Promising clinical progress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Alzinova | Alzinova AB interim report January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Alzinova | Alzinova AB delårsrapport för januari - mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Alzinova | BioStock: Fortsatt robusta interimdata i Alzinovas Alzheimerstudie | Pressreleaser | Visa Stäng |
|